# Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

> **NCT02149303** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 191 (actual)

## Conditions studied

- Atrial Fibrillation
- Hemorrhage

## Interventions

- **DRUG:** Dabigatran 75 mg
- **DRUG:** Dabigatran 150 mg

## Key facts

- **NCT ID:** NCT02149303
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2016-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149303, "Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02149303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*